INTRODUCTION
Extranodal, natural killer (NK)/T-cell lymphoma1, formerly known as angiocentric lymphoma2,3, is much more common in Asia and Latin America than in the United States and Europe1-4. In Japan, nasal NK/T-cell lymphoma accounts for 1.85% of all malignant lymphomas and NK/T-cell lymphoma of extranodal sites, other than the nose, accounts for 0.75%5. Extranodal NK/ T-cell lymphoma is an Epstein-Barr virus (EBV)-associated neoplasm that is believed to consist of NK cells in most cases and possibly of T cells in others2,3. NK/T-cell lymphoma of extranodal sites other than the nose is reported to be incurable and is almost always fatal6,7, while nasal NK/T-cell lymphoma has a more favorable outcome. Reported 5-year overall survival rates of nasal NK/T-cell lymphoma have ranged from 14 to 87%6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Approximately 90% of patients with nasal NK/Tcell lymphoma present with localized disease6, and the prognosis of patients with relapsed disease is extremely poor20. Therefore, a more effective therapeutic regimen for localized nasal NK/T-cell lymphoma is needed.
In many studies, lymphomas arising in the nasal cavity and paranasal sinuses were not evaluated separately because it has been believed that any differences between them were not apparent25. Moreover, 'true' NK-cell lymphoma, peripheral T-cell lymphoma, and B-cell lymphoma were often included in one study because of the difficulty in immunophenotyping.
Therefore, the specific therapeutic outcome of nasal NK-cell lymphoma has not been thoroughly examined. Nasal NK/T-cell lymphoma is known to be resistant to conventional chemotherapy, and according to the literature most patients have been treated with radiotherapy (RT) with or without chemotherapy6,8-24. However, the details of treatment, especially the timing of RT and chemotherapy, are uncertain in many reports.
To clarify treatment details we retrospectively reviewed the clinical courses of consecutivelydiagnosed cases of localized nasal NK-cell lymphoma.
Patients, Materials and Methods

Patients
Between 1988 and 2000, we diagnosed 12 patients with nasal NK-cell lymphoma. Eight patients (Cases 1-8) were included in our previous report concerning immunophenotypes26. Nasal tissue and/or lymph node specimens were obtained from patients after informed consent. Immunohistochemical staining with frozen sections was performed in all cases.
Histology and Immunohistochemistry
Histological diagnosis was carried out on hematoxilin-eosin stained, 10% formalin-fixed sections according to the WHO classification1. The immunophenotypic study of tumor cells was performed using a labeled avidin-biotin method on the frozen sections, as described previously 27. New fuchsin and naphthol AS-BI phosphate were used as substrate-chromogen reagents. Sections were counterstained with Gill's hematoxylin. The monoclonal antibodies used were Leu5b (CD2), Leu4 (CD3), and Leu 1 (CD5), (Becton Dickinson, Mountain View, CA); NKH 1 (CD56) (Coulter, Hialeah, FL); CD3, L26 (CD20), and LCA (CD45), (DAKO, Carpinteria, CA).
Management
Seven patients were initially treated by combination chemotherapy (Group 1), and the remaining five patients were started on RT as soon as possible after diagnosis (Group 2). Three of them received consolidation chemotherapy after RT. Since 1998, patients have been treated concurrently with RT and chemotherapy.
All treatment protocols in RT used a conventional fraction schedule of 1.5-2.0 Gy/day, five times per week. The planned total dose to the involved area was 40-50 Gy. For patients with stage II disease the fields were extended to encompass the involved paranasal sinuses or cervical lymph nodes. Three patients received prophylactic cervical lymph node irradiation.
Nine patients received chemotherapy with anthracycline-containing regimens, and three were treated with a combination of carboplatin (CBDCA), etoposide (VP16), ifosfamide (IFM), and dexamethasone (DMX) [DeVIC]28.
Clinical response was evaluated after induction therapy. A complete response (CR) was defined as the disappearance of all clinical evidence of disease and normalization of all laboratory values and image studies.
Statistics
Duration of survival was calculated from the time of diagnosis to the date of last follow-up or death. Overall survival was analyzed by the KaplanMeier method and was compared by means of the log-rank test.
Results
Patient characteristics of the 12 nasal NK-cell lymphoma cases
Twelve patients were diagnosed with nasal N K-cell lymphoma.
All patients revealed a phenotype of CD2+CD3(Leu4)-cytoplasmic CD3E+CD5-CD45+CD56+.
The clinical features at presentation of these 12 patients with nasal NK-cell lymphoma are summarized in Table 1 . Eight were male and four were female. The median age was 64/65 years, with a range of 41 to 78. Five patients (Cases 1, 4, 10, and 12) had only intranasal disease at presentation.
In six patients, tumors extended beyond the nasal cavity and into neighboring sites, such as the paranasal sinuses, palate, and epipharynx.
Three patients had involvement of cervical lymph nodes. Nine patients were stage I, and three stage II. Five patients presented with B symptoms. Serum LDH level was elevated in three patients, and performance status was higher than one in two patients. According to the International Prognostic Index29, six patients were classified as having low, five low intermediate, and one high. Therapeutic outcome of patients initially treated with RT (Group 2) Table 3 shows the therapeutic outcomes of patients initially treated with RT. Three patients were treated with RI and consolidation chemotherapy. Anthracycline-containing regimens were used in two patients: VEPA-B and M-FEPA in case 1, cyclophosphamide, epirubicin, vincristine, VP16, and prednisolone (CEOP plus VP16) in Case 2. One patient (Case 7) was treated with DeVIC after RT. Two patients diagnosed after 1998 were treated with RI and DeVIC concurrently. All five achieved CR. One patient (Case 1) died of relapsed lymphoma 19 months after diagnosis, the others are alive with no evidence of recurrence.
One patient (Case 11) who showed B symptoms (elevated fever, night sweats, and weight loss: 8kg/ 3 mo) and elevated serum LDH level received RTDeVIC therapy. He was treated with 45 Gy of local RT, and simultaneously initiated with six courses of DeVIC therapy (CBDCA 300mg/m2 iv Day 1, VP16 100mg/m2 iv Day 1-3, IFM 1.5g/m2 iv Day 1-3, and DMX 40mg/body iv Day 1-3; every 21 days). His nasopalatal and pharyngeal masses disappeared Table 3 . Therapeutic outcome of patients initially treated with RT (Group 2) within one month after initial therapy, and clinical symptoms and abnormal findings on laboratory data improved rapidly and returned to normal after three courses of chemotherapy.
Mucositis (Grade 3) developed during the third and fourth courses of DeVIC. There is no evidence of recurrence 32 months after diagnosis.
Another patient treated with RT-DeVIC therapy (Case 12) was an elderly female. She was treated with 40 Gy of local RT, and simultaneously initiated with three courses of DeVIC therapy (75% dose). Her nasal mass disappeared within one month after initiating therapy.
Sinusitis (Grade 2) developed temporarily, but was resolved completely by medication. There is no evidence of recurrence 12 months after her diagnosis.
Survival
The 5-year overall survival rate was 39% (Fig.  1) . Patients who received RT first (Group 2) showed a survival curve significantly superior to that for patients who received chemotherapy (Group 1) (P= .017, Fig. 2 In patients who received only RT, the 5-year overall survival rates were approximately 40% 8,20. Therefore, RT alone is not sufficient to obtain a cure. Patients who were treated with RT followed by chemotherapy seemed to exhibit a good prognosis12,14,18,21, similar in outcome to ours. Based on the present study and a review of the literature, RT is highly recommended as the first therapy for localized nasal N K-cell lymphoma.
We have used RT-DeVIC therapy as our firstline therapy for localized nasal NK-cell lymphoma since 1998. RT-DeVIC is a concurrent regimen consisting of involved-field RT and DeVIC. DeVIC was designed as a salvage chemotherapeutic regimen for aggressive non-Hodgkin's lymphoma28.
Previously, we examined the expression of Pglycoprotein, which is the product of the multi-drug resistance (MDR) 1 gene30,31 in nasal NK/T-cell lymphoma cells, to clarify the mechanisms of drug resistance32. We found frequent expression of Pglycoprotein on nasal NK/T-cell lymphoma cells. Therefore, we can recommend not using MDRrelated drugs or using P-glycoprotein/MDR1 modulators for nasal NK/T-cell lymphoma. The reason we selected DeVIC as a chemotherapeutic regimen for nasal NK-cell lymphoma is that DeVIC consists of CBDCA and IFM, which are MDR-unrelated anticancer agents33,34 Indeed, DeVIC showed temporary efficacy in a patient with refractory NK/ T-cell lymphoma.
As in our Cases 8 and 9, highly aggressive cases of localized nasal NK-cell lymphoma do exist. In fact, the reported survival curve of nasal lymphoma declines within a few months after diagnosis6,8,13,16. Since we speculated that RT and chemotherapy separately are insufficient for such highly aggressive cases, we designed RT-DeVIC therapy to be a concurrent treatment with RT and chemotherapy. Concurrent therapies are commonly used in nonhematologic malignancies, for example in esophageal cancer35 and lung cancer36. Since CBDCA enhances the efficacy of RT37, it is widely used with RT. Our two patients treated with RT-DeVIC therapy did not show any severe adverse effects. Although they showed a high serum LDH level and/ or B symptoms, they achieved CR.
From the results of this study and a review of the literature, RT is highly recommended as an initial therapy for localized nasal NK-cell lymphoma.
The efficacy of RT-DeVIC therapy should be evaluated by a prospective, multiinstitutional study.
